Search results for "response"

showing 10 items of 4136 documents

Effect of β-cryptoxanthin plus phytosterols on cardiovascular risk and bone turnover markers in post-menopausal women: a randomized crossover trial.

2014

Abstract Background and aim Post-menopausal women are at higher risk of cardiovascular disease and bone demineralization. Phytosterols (PS) may be used for hypercholesterolemia in some groups and β-cryptoxanthin (β-Cx) displays a unique anabolic effect on bone. Our aim was to assess the changes in cardiovascular and bone turnover markers from the oral intake of β-Cx and PS in post-menopausal women. Methods and results A randomized, double-blind, crossover study with β-Cx (0.75 mg/day) and PS (1.5 g/day), single and combined, was performed in 38 postmenopausal women. Diet was supplemented with 1 × 250 mL milk-based fruit drink/day for 4 weeks with a wash-out period of 4-weeks in between. Ser…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismCampesterolOsteoporosisHypercholesterolemiaMedicine (miscellaneous)Parathyroid hormoneAdministration OralGastroenterologyBone and BonesBone remodelingchemistry.chemical_compoundDouble-Blind MethodRisk FactorsInternal medicineStatistical significancemedicineHumansCryptoxanthinsTriglyceridesAgedNutrition and DieteticsCross-Over StudiesDose-Response Relationship Drugbusiness.industryCholesterol HDLPhytosterolsCholesterol LDLMiddle Agedmedicine.diseaseCrossover studySitosterolsHealthy VolunteersClinical trialPostmenopauseEndocrinologyCholesterolTreatment OutcomechemistrySelective estrogen receptor modulatorCardiovascular DiseasesDietary SupplementsFemaleCardiology and Cardiovascular MedicinebusinessNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Similar efficacy of low and standard doses of transdermal estradiol in controlling bone turnover in postmenopausal women

2006

To investigate the effects of a low transdermal estradiol dose on bone metabolism and to compare it with both the standard dose and absence of treatment.In this study performed in a third-level academic center, 66 healthy postmenopausal women underwent hormone therapy (HT) with patches containing estradiol at standard (0.050 mg/day, HT50, 33 women) or low dosage (0.025 mg/day, HT25, 33 women) and 70 women were without treatment (NT). The values (mean of three samples) of several bone biochemical parameters were compared between groups after adjusting for confounding factors. Bone mineral density (BMD) was assessed (by dual-energy X-ray absorptiometry) in the spine and hip in all cases, and …

medicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisCollagen Type IBone remodelingEndocrinologyBone DensityInternal medicinemedicineHumansOsteoporosis PostmenopausalTransdermalBone mineralAnalysis of VarianceDose-Response Relationship DrugEstradiolbusiness.industryEstrogen Replacement TherapyObstetrics and GynecologyMiddle AgedAlkaline Phosphatasemedicine.diseasePostmenopauseMenopauseDose–response relationshipEndocrinologyFemaleHormone therapyPeptidesDensitometrybusinessBiomarkersGynecological Endocrinology
researchProduct

Raloxifene promotes prostacyclin release in human endothelial cells through a mechanism that involves cyclooxygenase-1 and -2

2005

Objective To examine the effects of raloxifene on prostacyclin production by human umbilical vein endothelial cells (HUVEC) and to shed light on the molecular details of that action. Design Cell culture for 4, 8, 16, 24, and 48 hours. Setting University research laboratory. Patient(s) Source of HUVEC. Intervention(s) Measurement of prostacyclin production and of protein levels and mRNA expression of cyclooxygenase (COX)-1 and -2. Main Outcome Measure(s) Prostacyclin production was measured by enzyme immunoassay, the mRNA expression of COX-1 was measured by quantitative real time-polymerase chain reaction, and the protein levels of COX-1 and -2 were measured by immunoblotting. Result(s) Ralo…

medicine.medical_specialtyEndotheliumAgonist-antagonistEstrogen receptorProstacyclinPharmacologyGene Expression Regulation EnzymologicUmbilical veinInternal medicinemedicineHumansCyclooxygenase InhibitorsRaloxifeneCells CulturedDose-Response Relationship DrugbiologyChemistryEndothelial CellsObstetrics and GynecologyEpoprostenolEndothelial stem cellmedicine.anatomical_structureEndocrinologyReproductive MedicineCyclooxygenase 2Raloxifene HydrochlorideCyclooxygenase 1biology.proteinCyclooxygenasemedicine.drugFertility and Sterility
researchProduct

Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?

2011

Abstract The history of ascorbic acid (AA) and cancer has been marked with controversy. Clinical studies evaluating AA in cancer outcome continue to the present day. However, the wealth of data suggesting that AA may be highly beneficial in addressing cancer-associated inflammation, particularly progression to systemic inflammatory response syndrome (SIRS) and multi organ failure (MOF), has been largely overlooked. Patients with advanced cancer are generally deficient in AA. Once these patients develop septic symptoms, a further decrease in ascorbic acid levels occurs. Given the known role of ascorbate in: a) maintaining endothelial and suppression of inflammatory markers; b) protection fro…

medicine.medical_specialtyEndotheliummedicine.medical_treatmentlcsh:MedicineInflammationReviewAscorbic AcidMicrobiologyGastroenterologyGeneral Biochemistry Genetics and Molecular BiologySepsisNeoplasmsSepsisInternal medicinemedicineHumansEndotheliumAscorbic Acid DeficiencyCancerImmunology and Infectious DiseaseMedicine(all)Biochemistry Genetics and Molecular Biology(all)business.industrylcsh:RImmunityCancerGeneral Medicinemedicine.diseaseAscorbic acidSystemic inflammatory response syndromemedicine.anatomical_structureOncologyInjections IntravenousImmunologyAscorbic Acid DeficiencyIntravenous ascorbic acidmedicine.symptombusinessAdjuvantJournal of Translational Medicine
researchProduct

Cardiometabolic non-response to aerobic exercise: Identifying subclinical ischaemic coronary disease

2019

Sin financiación 5.864 JCR (2019) Q1, 18/138 Cardiac & Cardiovascular Systems 1.459 SJR (2019) Q1, 58/362 Cardiology and Cardiovascular Medicine; Q2, 36/104 Epidemiology No data IDR 2019 UEM

medicine.medical_specialtyEpidemiologyEnfermedad cardiovascularCardiologyMEDLINECardiometabolic responseCoronary Artery DiseaseCoronary diseaseCoronary artery diseaseInternal medicineDiabetes mellitusmedicineHumansAerobic exerciseExerciseCardiometabolic response aerobic exercise coronary disease.Subclinical infectionMetabolismobusiness.industrymedicine.diseaseaerobic exerciseDiabetes Mellitus Type 2coronary disease.Cardiovascular DiseasesCardiologyCardiopatía coronariaCardiology and Cardiovascular MedicinebusinessEuropean Journal of Preventive Cardiology
researchProduct

Characteristics of histamine tachyphylaxis in rat uterine smooth muscle.

2002

Objective and design: To study both the desensitisation induced by short-term exposure to histamine and the mechanism responsible in the isolated rat uterus.¶Material: Precontracted isolated uterus (37 mM KCl) from oestrogenised Wistar rats were used.¶Treatment: Repetitive responses to histamine (10–6, 10–5, 10–4, 10–3 M), dimaprit and clonidine (10–4 M) were tested at 15, 30, 45 and 105 min., with their modifications by (5 mg/ kg, 24 h before sacrifice) reserpine, 10–7 M propranolol, 10–8 M atropine, and 10–6 M indomethacin. Dose-response curves for adrenaline were carried out as standard protocol.¶Methods: In vitro techniques (de Jalon's solution, 31°C, carbogen, isotonic registration, re…

medicine.medical_specialtyEpinephrineMuscle RelaxationImmunologyPropranololTachyphylaxisIn Vitro TechniquesClonidineHistamine Agonistschemistry.chemical_compoundUterine ContractionDimapritInternal medicinemedicineCyclic AMPAnimalsIsotonic ContractionRats WistarTachyphylaxisPharmacologyDose-Response Relationship Drugbusiness.industryUterusEstrogensReserpineDimapritClonidineRatsAtropineDose–response relationshipEndocrinologychemistryFemalebusinessAdrenergic alpha-AgonistsHistaminemedicine.drugHistamineInflammation research : official journal of the European Histamine Research Society ... [et al.]
researchProduct

Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia

2018

Background: Intravenous immunoglobulin (IVIG) IQYMUNE® is a highly purified 10% IVIG that was assessed using the new stringent definition of response described in the revised guideline on the clinical investigation of IVIG. The efficacy and the safety of IQYMUNE® were investigated in adult patients with chronic primary immune thrombocytopenia (ITP). Methods: In this phase III multinational, multicentre, prospective, uncontrolled, open-label, single-arm study, adult patients with a baseline platelet count < 30 × 10 9 /L were treated with IVIG 10% at a dose of 2 g/kg body weight administered over 2 consecutive days. The primary endpoint was Response over the study period and was defined accor…

medicine.medical_specialtyEuropean Medicines Agency guidelinesPlatelet countRenal functionHigh dose030204 cardiovascular system & hematologyGastroenterology03 medical and health sciencesIntravenous immunoglobulin; High dose; Immune thrombocytopenia; Response; European Medicines Agency guidelines; Platelet count; Bleeding assessment; Infusion rate0302 clinical medicineInfusion rateInternal medicinemedicineClinical endpointPlateletAdverse effectIntravenous immunoglobulinbiologybusiness.industryResponseGuidelineImmune thrombocytopeniaImmune thrombocytopenia030220 oncology & carcinogenesisConcomitantbiology.proteinBleeding assessmentOriginal ArticleAntibodybusinessJournal of Hematology
researchProduct

Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis

2022

Background: Benralizumab is effective in severe eosinophilic asthma (SEA), but suboptimal responses are observed in some patients. Although several factors have been associated with benralizumab response, no cluster analysis has yet been undertaken to identify different responsiveness sub-phenotypes. Objective: To identify SEA sub-phenotypes with differential responsiveness to benralizumab. Methods: One hundred and five patients diagnosed with SEA who had completed 6 months of benralizumab treatment were included in a hierarchical cluster analysis based on a set of clinical variables that can be easily collected in routine practice (age, age at disease onset, disease length, allergen sensit…

medicine.medical_specialtyExacerbationbiologicals monoclonal antibodies observational studies precision medicine real-lifeprecision medicineImmunologyDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioImmunoglobulin EAntibodies Monoclonal Humanizedobservational studiechemistry.chemical_compoundInternal medicinemedicineImmunology and AllergyCluster AnalysisHumansAnti-Asthmatic Agentsreal-lifeobservational studiesmonoclonal antibodieResponse rate (survey)Bronchiectasisbiologybusiness.industrymedicine.diseaseBenralizumabPhenotypeAsthmaEosinophilsPhenotypechemistrybiologicalsbiology.proteinDisease ProgressionBiomarker (medicine)monoclonal antibodiesbusinessbiological
researchProduct

Inhibition of intracellular Ca2+ release by a Rho-kinase inhibitor for the treatment of ischemic damage in primary cultured rat hippocampal neurons.

2008

The effects of hydroxy fasudil, a specific Rho-kinase inhibitor, on behavior and brain neuronal activity in animal studies have been described previously. However, whether a Rho-kinase inhibitor can directly protect neurons against ischemic damage and the molecular mechanisms underlying these effects are poorly understood. The present work was designed to investigate the effect of hydroxy fasudil against oxygen-glucose deprivation (OGD) induced acute neuronal injury and the underlying mechanisms in vitro. Pretreatment with hydroxy fasudil at 5 and 10 microM could concentration-dependently improve cell viability and decrease Lactate dehydrogenase (LDH) level in extracellular solution of neur…

medicine.medical_specialtyExcitotoxicityIntracellular SpaceGlutamic AcidBiologymedicine.disease_causeNeuroprotectionHippocampusCalcium in biologyPotassium ChlorideRats Sprague-DawleyCalcium imagingAdenosine TriphosphateIschemiaInternal medicine1-(5-Isoquinolinesulfonyl)-2-MethylpiperazinemedicineAnimalsHypoxiaProtein Kinase InhibitorsCells CulturedPharmacologyNeuronsrho-Associated KinasesDose-Response Relationship DrugCalcium channelFasudilGlutamate receptorRatsEndocrinologyGlucoseRho kinase inhibitorCalciumEuropean journal of pharmacology
researchProduct

Effects of three different water temperatures on dehydration in competitive swimmers

2011

Summary Aims The purpose of this study was to evaluate the effects of three different water temperatures on physiological responses (dehydration, sweat rate, urine output, rectal temperature and plasma electrolytes) of competitive athletes during a “simulated” race of 5 km in an indoor swimming pool. Methods Nine male competitive master swimmers swam 5 km with the water at temperatures of 23, 27 and 32 C. Immediately before (Pre) and after (Post) each trial, samples of blood and urine were collected, body weight was recorded and rectal temperature was measured. The dehydration percentage and sweat rate were the highest at 32 C and the lowest at 23 C (23 C: −0.9 ± 0.5; 27 C: −1.3 ± 0.6; 32 C…

medicine.medical_specialtyFluid balance body temperatures plasma electrolytesSettore BIO/16 - Anatomia UmanaChemistryRectal temperatureUrinemedicine.diseaseBody weightSettore BIO/09 - Fisiologiafluid balancePhysiological responsesSurgeryrectal temperatureSWEATopen water; swimming; sweat rate; fluid balance; performance; rectal temperatureAnimal scienceOpen watersweat rateopen watermedicineOrthopedics and Sports MedicineDehydrationswimmingperformanceUrine outputScience &amp; Sports
researchProduct